Leerink lifts target to USD 365.00 for Labcorp stock

Published on 10/20/2026 at 19:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue rose 5.80 percent to USD 3.73 billion. Labcorp stock costs EUR 287.00 on October 20, 2026 at 7:51 p.m. CEST.

Analyst target and earnings date

Leerink Partners raised its Labcorp target from USD 350.00 to USD 365.00 on October 8, 2026.
Second-quarter revenue increased 5.80 percent to USD 3.73 billion.
Labcorp stock costs EUR 287.00 at Lang & Schwarz on October 20, 2026 at 7:51 p.m. CEST.
Labcorp will report third-quarter results on October 28, 2026.

Modernes Diagnostiklabor mit Technikern in weißen Kitteln an automatisierten Analysegeräten — Labcorp (ISIN US50540R4092) betreibt moderne klinische Labore mit Technikern und automatisierten Diagnosegeräten hinter Glasfassaden, Illustration mit AI erstellt.

Leerink Partners raised its target for Labcorp stock from USD 350.00 to USD 365.00 on October 8, 2026, as MarketScreener reported. The target is 13.02 percent above the USD 322.94 NYSE quote for October 20, 2026. The euro price was EUR 287.00 at Lang & Schwarz on October 20, 2026 at 7:51 p.m. CEST.

Revenue growth supports the case

Labcorp generated USD 3.73 billion in second-quarter 2026 revenue, up 5.80 percent from the same quarter a year earlier. Adjusted earnings per share reached USD 4.99, an increase of 14.90 percent, while adjusted operating margin rose to 15.80 percent from 15.10 percent, according to Yahoo Finance.

The latest reported quarter also included USD 314.00 million in free cash flow. Labcorp raised its 2026 adjusted earnings-per-share guidance to a range of USD 18.10 to USD 18.55 during the second-quarter update.

What does USD 365.00 imply?

The analyst target sits above the current USD 322.94 NYSE quote, but the distance is narrower than the gap to the 12-month high of USD 341.80. The same quote was within the USD 244.52 to USD 341.80 range on October 20, 2026, leaving the stock 5.52 percent below its high.

Labcorp's market capitalization was USD 26.2 billion and its price-to-earnings ratio was 26.72 on October 20, 2026. The NYSE quote stood at USD 322.94 at 1:57 p.m. ET, with 213,074 shares traded at that time.

October 28 results set the next date

Labcorp is scheduled to release third-quarter 2026 results before the market opens on October 28, 2026, followed by a conference call at 9:00 a.m. ET, according to the company's Labcorp release dated September 30, 2026. MarketBeat lists consensus estimates of USD 4.64 in earnings per share and USD 3.76 billion in revenue for the quarter, versus USD 4.18 and USD 3.56 billion a year earlier.

Comparison with peers

Labcorp: up 1.29 percent on October 20, 2026, P/E 26.72, market capitalization USD 26.2 billion.

Quest Diagnostics (NYSE, USD): up 0.43 percent on October 20, 2026, P/E 25.04, market capitalization USD 26.0 billion.

Charles River Laboratories (NYSE, USD): up 5.12 percent on October 20, 2026, market capitalization USD 15.2 billion.

Market position and next catalyst

Labcorp combines diagnostics with drug-development services, so the October 28 report will put the 5.80 percent second-quarter revenue increase and the USD 18.10 to USD 18.55 adjusted earnings-per-share outlook into a new operating-period test. The USD 365.00 analyst target provides a measurable valuation reference, while the USD 341.80 12-month high marks the nearer market threshold.

The further course of trading is shown by the continuously updated real-time quote of Labcorp stock.